Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer Immunology, Immunotherapy

Volumn 57, Issue 12, 2008, Pages 1817-1825

  Amin, Asna ^a   Benavides, Linda C ^b   Holmes, Jarrod P ^c   Gates, Jeremy D ^b   Carmichael, Mark G ^d   Hueman, Matthew T ^d   Mittendorf, Elizabeth A ^e   Storrer, Catherine E ^d   Jama, Yusuf H ^d   Craig, Dianna ^f   Stojadinovic, Alex ^a   Ponniah, Sathibalan ^d   Peoples, George E ^b,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Windber Medical Center   (United States)

Author keywords

E75 peptide; Immunologic response; Pathologic patterns; Preventive; Recurrence; Vaccine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA A3 ANTIGEN; PEPTIDE E75; PEPTIDE VACCINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; FOLLOW UP; HLA TYPING; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK;

ADJUVANTS, IMMUNOLOGIC; BREAST NEOPLASMS; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; KAPLAN-MEIERS ESTIMATE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; VACCINES, SUBUNIT;

EID: 52549085726     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0509-2     Document Type: Article

References (33)

1. LA Emens RT Reilly EM Jaffee 2005 Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr Relat Cancer 12 1 17
2. EA Mittendorf CE Storrer CD Shriver 2006 Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer Ann Surg Oncol 13 1085 1098
3. A Iannelo A Ahmad 2005 Role of antibody-dependent cell-mediated cytotoxicty in the efficacy of therapeutic anti-cancer monoclonal antibodies Cancer Metastasis Rev 24 487 499
4. MJ Piccart-Gebhart M Procter B Leyland-Jones 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672
5. Romond Eh EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
6. B Fisk TL Blevins JT Wharton 1995 Identification of immunodominant peptide of the HER2/neu proto-oncogene recognized by ovarian tumor-specific CTL lines J Exp Med 181 2109 2117
7. TZ Zaks SA Rosenberg 1998 Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors Cancer Res 58 4902 4908
8. KL Knutson K Schiffman MA Cheever 2002 Immunization of cancer patients with HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity Clin Cancer Res 8 1014 1018
9. JL Murray ME Gillogly D Przepiorka 2002 Toxicity, immunogenicity, and induction of E75-specific tumorlytic CTLs by HER-2 peptide E74 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2 + patients with metastatic breast and ovarian cancer Clin Cancer Res 8 3407 3418
10. D Avigan B Vasir J Gong 2004 Fusion cell vaccination of patients with metastatic breast and renal cell cancer induces immunological responses Clin Cancer Res 10 4699 4708
11. ML Disis TA Gooley K Rinn 2002 Generation of T-cell immunity to the HER2/neu protein after active immunization with HER2/neu peptide-based vaccines J Clin Oncol 20 2624 2632
12. ML Disis KH Grabstein PR Sleath 1999 Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 1289 1297
13. GE Peoples JM Gurney MT Hueman 2005 Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients J Clin Oncol 23 7536 7545
14. GE Peoples JP Holmes MT Hueman 2008 Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients Clin Cancer Res 14 797 803
15. GE Peoples S Khoo ZA Dehqanzada 2006 Combined clinical trial results of a HER2/neu (E75) vaccine for prevention of recurrence in high-risk breast cancer patients [abstract] Br Cancer Res Treat 100 3
16. M Mori PG Beatty M Graves 1997 HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Registry 1 Transplantation 64 1017 1027
17. KC Parker MA Bednarek JE Coligan 1994 Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J Immunol 152 163 175
18. HG Rammensee J Bachmann NP Emmerich OA Bachor S Stevanovi 1999 SYFPEITHI: database for MHC ligands and peptide motifs Immunogenetics 50 213 219
19. + breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I clinical trial [abstract]. Breast Cancer Res Treat
20. + T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients J Clin Immunol 24 449 461
21. JE Sokal 1975 Measurement of delayed skin-test responses N Engl J Med 293 501 502
22. M Kimura Y Yanagita T Fujisawa 2007 Study of time-course changes in annual recurrence rates for breast cancer: data analysis of 2, 209 patients for 10 years post-surgery [abstract] Breast Cancer Res Treat 106 3 407 411
23. T Saphner D Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 2738 2746
24. T Nemoto J Vana N Ramez 1980 Management and survival of female breast cancer: results of a national survey by the American College of Surgeons Cancer 45 2917 2924
25. CW Ellston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410
26. ® (STn-KLH) as treatment for breast cancer Expert Rev Vaccines 3 655 663
27. MB Faries 2006 Evaluation of immunotherapy in the treatment of melanoma Surg Oncol N Am 15 399 418
28. T Jordan G Sunderam L Thomas LB Reichman 1987 Tuberculin reaction size measurements by the pen method compared to traditional palpation Chest 92 234 236
29. CE Storrer MT Hueman JM Gurney 2004 Comparison of HLA-A2 dimer and tetramer molecules for the immunological monitoring of breast and prostate cancer vaccine clinical trials Clin Invest Med 27 211D
30. V Patanaphan OM Salazar R Risco 1988 Breast cancer: metastatic patterns and their prognosis South Med J 81 1109 1112
31. AF Jacobson CL Shapiro AD Van den Abbeele WD Kaplan 2001 Prognostic significance of the numbers of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma Cancer 91 17 24
32. BK Park H Zhang Q Zeng 2007 NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF Nature Med 13 62 69
33. F Di Rosa R Pabst 2005 The bone marrow: a nest for migratory memory T cells Trends Immunol 26 360 366